Zhitong Finance App News, Shiyao Group (01093) issued an announcement regarding the signing of a strategic research and development cooperation agreement (this agreement) between the Group and AstraZeneca to discover and develop novel oral small molecule drug candidates. Unless otherwise defined, the terms used in this Notice have the same meaning as those defined in this Notice.

As disclosed in the announcement, the Group agreed to discover preclinical drug candidates (PCC) with the potential to treat multiple indication diseases for multiple targets selected by AstraZeneca, including a preclinical small molecule oral therapy for immune diseases.

The Group received a milestone payment of $10 million from AstraZeneca on August 5, 2026 to exercise the licensing option for one of the PCC projects under the terms of the agreement, indicating that related R&D work under the agreement is progressing steadily as planned.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.